Nature Communications (Dec 2022)
Modulating glycosphingolipid metabolism and autophagy improves outcomes in pre-clinical models of myeloma bone disease
- Houfu Leng,
- Hanlin Zhang,
- Linsen Li,
- Shuhao Zhang,
- Yanping Wang,
- Selina J. Chavda,
- Daria Galas-Filipowicz,
- Hantao Lou,
- Adel Ersek,
- Emma V. Morris,
- Erdinc Sezgin,
- Yi-Hsuan Lee,
- Yunsen Li,
- Ana Victoria Lechuga-Vieco,
- Mei Tian,
- Jian-Qing Mi,
- Kwee Yong,
- Qing Zhong,
- Claire M. Edwards,
- Anna Katharina Simon,
- Nicole J. Horwood
Affiliations
- Houfu Leng
- Kennedy Institute of Rheumatology, University of Oxford
- Hanlin Zhang
- Kennedy Institute of Rheumatology, University of Oxford
- Linsen Li
- Key Laboratory of Cell Differentiation and Apoptosis of Chinese Ministry of Education, Department of Pathophysiology, Shanghai Jiao Tong University School of Medicine
- Shuhao Zhang
- Kennedy Institute of Rheumatology, University of Oxford
- Yanping Wang
- Institutes of Biology and Medical Sciences, Soochow University
- Selina J. Chavda
- Department of Hematology, UCL Cancer Institute, University College London
- Daria Galas-Filipowicz
- Department of Hematology, UCL Cancer Institute, University College London
- Hantao Lou
- Ludwig Institute for Cancer Research, Nuffield Department of Medicine, University of Oxford
- Adel Ersek
- Norwich Medical School, University of East Anglia
- Emma V. Morris
- Nuffield Department of Surgical Sciences, Botnar Research Centre, University of Oxford
- Erdinc Sezgin
- Science for Life Laboratory, Department of Women’s and Children’s Health, Karolinska Institute
- Yi-Hsuan Lee
- Kennedy Institute of Rheumatology, University of Oxford
- Yunsen Li
- Institutes of Biology and Medical Sciences, Soochow University
- Ana Victoria Lechuga-Vieco
- Kennedy Institute of Rheumatology, University of Oxford
- Mei Tian
- Human Phenome Institute, Fudan University
- Jian-Qing Mi
- Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, RuiJin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine
- Kwee Yong
- Department of Hematology, UCL Cancer Institute, University College London
- Qing Zhong
- Key Laboratory of Cell Differentiation and Apoptosis of Chinese Ministry of Education, Department of Pathophysiology, Shanghai Jiao Tong University School of Medicine
- Claire M. Edwards
- Nuffield Department of Surgical Sciences, Botnar Research Centre, University of Oxford
- Anna Katharina Simon
- Kennedy Institute of Rheumatology, University of Oxford
- Nicole J. Horwood
- Kennedy Institute of Rheumatology, University of Oxford
- DOI
- https://doi.org/10.1038/s41467-022-35358-3
- Journal volume & issue
-
Vol. 13,
no. 1
pp. 1 – 18
Abstract
Here, the authors show that the glycosylceramide synthesis inhibitor and FDA approved drug Eliglustat inhibits autophagic degradation of TRAF3 which is a key step for osteoclast differentiation and thereby improves myeloma bone lesions.
